Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ACTengine® IMA203CD8 GEN2 (PRAME) in Ovarian Cancer. The expected timing is based on the latest available company guidance and may change.
04/21/26:- ASCO abstracts May 21; IMA203CD8 Ph1a ovarian cancer results oral May 30, 2026. 05/12/26:- Updated Ph1a/1b IMA203CD8 gynecologic cancer data at ASCO 2026; dose escalation and RP2D completion remain planned for 2026. 05/30/26:- NCT03686124 Ph1 gynecologic ORR 63%, cORR 50%. Follow-up at RP2D planned H2 2026. RP2D expected 2026. 07/17/26:- ESMO 2026 Phase 1 IMA203CD8 results abstract Oct 19; oral Oct 23, 2026. 08/18/26:- Phase 1 gynecologic cancer data showed 63% response rate. Updated data will be presented at ESMO 2026.
Verification
Confirm timing and program details against the company announcement or filing.